News

Novartis1d
Novartis completes acquisition of Regulus Therapeutics
We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...
Novartis24d
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™ plus ...
Novartis1mon
Why advocating for your MS is so important | Novartis
For the estimated 2.8 million people 1 living with multiple sclerosis (MS) worldwide, diagnosis is life-altering and can be overwhelming. The symptoms, including loss of vision, movement and sensation ...
Novartis1mon
Vas Narasimhan named to 2025 TIME100 Health list | Novartis
Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health. Selected by ...
Novartis1mon
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal disease Lead asset for ADPKD ...
Novartis2mon
Novartis plans to expand its US-based manufacturing and R&D footprint with a total investment of $23B over the next 5 years
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities With new manufacturing capacity, Novartis will be able to produce 100% of its key ...
Novartis2mon
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA ...
Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1; Phase III data showed ...
Novartis3mon
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR. New indication approximately triples eligible patient population, allowing Pluvicto ® to be used after one androgen receptor pathway inhibitor (ARPI) and ...
Novartis3mon
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Phase III study showed sustained proteinuria reduction at one year with favorable safety 1; Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of ...
Novartis4mon
Good science is diverse and inclusive | Novartis
Innovation enables faster adaptation and response to changes, promotes growth, and distinguishes a company from its competitors. The foundation of breakthrough innovations and good science are diverse ...
Novartis4mon
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 | Novartis
Ad hoc announcement pursuant to Art. 53 LR. Full year. Net sales grew +12% (cc 1, +11% USD) with core operating income 1 up +22% (cc, +19% USD) . Sales growth driven by continued strong performance ...
Novartis7mon
Addressing unmet needs for inherited neuromuscular diseases
Acquisition of Kate Therapeutics enhances and strengthens Novartis strategic priorities in gene therapy and neuroscience innovation; Transaction includes enabling technology platforms and therapeutic ...